Molecular diagnostics market projected to reach $49.5 billion by 2035

The global molecular diagnostics market is projected to grow from $21.72 billion in 2026 to $49.50 billion by 2035, driven by reimbursement expansion, lower sequencing costs and wider use of companion diagnostics. North America leads now, while Asia-Pacific is expected to be the fastest-growing region through 2035.

Why it matters: - Molecular diagnostics is moving from specialized testing into routine care, especially in oncology, infectious disease and outpatient settings. - Broader payer coverage and lower sequencing costs are expanding access to genomic profiling and other molecular tests. - The market’s growth is tied to precision medicine adoption, which links diagnostics more directly to treatment decisions and reimbursement.

What happened: - Market Research Future estimates the global molecular diagnostics market will rise from $21.72 billion in 2026 to $49.50 billion by 2035. - The forecast implies a 9.58% compound annual growth rate from 2026 to 2035. - The market base was estimated at $19.82 billion in 2025. - The report says the expansion is being driven by payer reimbursement, sequencing cost declines, and regulatory momentum around companion diagnostics. - A free sample is available. - The full report is also available.

The details: - CMS’s 2024 National Coverage Determination expanded reimbursement for comprehensive genomic profiling across all advanced solid tumors. - The coverage change is projected to unlock an additional $1.2 billion in annual test volumes by 2027. - UnitedHealthcare and Aetna expanded molecular test coverage lists in 2024, covering more than 45 specific assays. - Whole-genome sequencing cost less than $200 per sample in late 2024, down from more than $1,000 five years earlier. - Compact benchtop sequencers can handle up to 48 samples per run, making high-throughput genomics more practical for mid-sized community hospitals. - The FDA approved 27 new companion diagnostic indications in 2024, the highest annual total on record. - CMS oncology reimbursement models and European stewardship programs are pushing hospitals toward multiplex syndromic panels and rapid sequencing platforms. - European consortium data cited in the report show syndromic panels can identify pathogens within 90 minutes, cut broad-spectrum antibiotic use by up to 30%, and lower antimicrobial costs per admission.

Between the lines: - The report shows a shift away from one-off testing and toward recurring, workflow-based molecular diagnostics tied to treatment pathways. - Reimbursement policy is now a major commercial lever, not just a back-office billing issue. - The strongest growth is coming from platforms that combine diagnosis with therapy selection, which raises the value of each test and deepens vendor lock-in. - The market remains concentrated, with the top five companies holding an estimated 52% to 58% combined revenue share. - Recent M&A, including Danaher’s integration of Cepheid and Roche’s acquisition of GenMark, has tightened competition.

What's next: - PCR remains the dominant technology, but next-generation sequencing is the fastest-growing segment at a 12.49% CAGR through 2035. - Oncology is the fastest-growing application segment at a 10.93% CAGR as liquid biopsy and companion diagnostics expand. - Instruments and systems are projected to grow fastest among product types at a 12.53% CAGR. - Clinics and ambulatory care are expected to be the fastest-growing end-user segment at 11.13% CAGR as point-of-care testing spreads. - North America remains the largest regional market, with about 45.50% share in 2025, while Asia-Pacific is forecast to grow fastest at 12.21% CAGR. - The report expects point-of-care molecular testing to exceed $6 billion by 2032.

The bottom line: - Molecular diagnostics is entering a broader commercial phase, with reimbursement, automation and companion diagnostics turning testing into a core part of modern care rather than a niche lab service.